Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — 36th Annual J.P. Morgan Healthcare Conference (January 2018)
20 slides from Nxera Pharma's conference presentation, Jan 8, 2018
Slide 1: Introduction to Sosei Group
Sosei Group Corporation 36 th Annual J.P. Morgan INTRODUCTION TO Healthcare SOSEI GROUP Conference 8 January 2018 July 2017
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed
Slide 3: A Japan-listed biotech with a difference
Listed 2004 in Tokyo (TSE Mothers: 4565) Global management team A Japan-listed biotech with a difference Main scientific campus in the U.K. Market capitalization: c.$2.0bn ➢ World-leader in GPCR-focused drug design based on unique IP protected StaR®1 GPCR technology & enabled SBDD2 platform ➢ Partne
Slide 4: Unique management team for a Japan-listed company
Unique management team for a Japan-listed company Significant pharma and biotech expertise Peter BAINS Dr. Malcolm WEIR Dr. Fiona MARSHALL Chief Executive Officer Chief R&D Officer Chief Scientific Officer Former Senior VP of International Commercial CEO and Co-Founder Heptares CSO and Co-Foun
Slide 5: Three corporate events have shaped Sosei
Three corporate events have shaped Sosei Our world-leading Partners 2005 2015 2017 Acquired Acquired Investment in Arakis Heptares Tx MiNA Tx (UK) (UK) (UK) ➢ Glycopyrrolate, later ➢ Platform: StaR® ➢ Platform: small licensed to NVS for technology for activating RNA respiratory products stabilising
Slide 6: Vast opportunity targeting GPCRs, however many high-value targets remain untapped
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Vast opportunity targeting GPCRs, however many high-value targets remain untapped GPCRs are the backbone of the pharma industry Neurological disorders c.400 non-olfactory GPCR targets in the
Slide 7: StaR technology enables us to stabilize and unlock GPCRs
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment StaR® technology enables us to stabilize and “unlock” GPCRs Revolution for GPCR structure-based discovery Difficulty drugging native/”wild-type” GPCRs Our solution: proprietary StaR® technolo
Slide 8: Risk-balanced strategy to leverage leadership and capitalize on GPCR opportunity
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Risk-balanced strategy to leverage leadership and capitalize on GPCR opportunity Creates and captures value Partnered (Traditional out-licensing/ ➢ Leverage strategic capabilities of partners
Slide 9: Advancing a Partnered GPCR pipeline in multiple therapeutic areas
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment : Current stage Advancing a Partnered GPCR pipeline in multiple therapeutic areas : Next 12–15 months progress Balanced and diversified Product/Program Modality Indication Partner Discovery P
Slide 10: Up to $6bn in potential economics secured from lead Partnered compounds
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Up to $6bn in potential economics secured from lead Partnered compounds Provides potential source of non-dilutive financing Upfront Total Total Sales Total UF + Milestones Program / received
Slide 11: Muscarinic M1 receptor agonist program for AD
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: Muscarinic M1 receptor agonist program for AD M1 AD A novel approach for symptomatic treatment of AD Phase 1b ➢ Donepezil inhibits cholinesterase, preventing the breakdown of
Slide 12: HTL0018318 is a potential first-in-class therapy for AD
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: HTL0018318 is a potential first-in-class therapy for AD M1 AD Highly selective M1 receptor agonist derived from StaR® and SBDD Phase 1b Overview of the HTL0018318 muscarinic M
Slide 13: Adenosine A2A antagonist program for cancer treatment
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: Adenosine A2A antagonist program for cancer treatment A2A Exciting I/O treatment approach Phase 1b I/O drugs – forecast sales for marketed products ($bn)1 Potential role of Ad
Slide 14: AZD4635 is a highly potent and selective A2A antagonist
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Partnered with: AZD4635 is a highly potent and selective A2A antagonist A2A The first A2A antagonist structurally derived from StaR® and SBDD Phase 1b Preclinical summary of AZD4635 Phase 1b
Slide 15: Proprietary pipeline now led by M1 DLB opportunity in Japan
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment : Current stage Proprietary pipeline now led by M1 DLB opportunity in Japan : Next 12–15 months progress Focus on selected rare/orphan and specialty indications or markets Product/Program Mod
Slide 16: Sosei is advancing HTL0018318 for DLB in Japan
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Sosei is advancing HTL0018318 for DLB in Japan M1 DLB Highly selective M1 receptor agonist designed by StaR® and SBDD Phase 2 ready Dementia with Lewy Bodies (DLB) Overview of our M1 program
Slide 17: Strategic investment in saRNA technology
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Strategic investment in saRNA technology CEBPA CEBPA1 is an attractive, previously ‘undruggable’ target in liver disease Phase 1/2a In May 2017, we acquired a strategic 25.6% stake in MiNA, w
Slide 18: Continuing to invest and scale the business
Business Partnered Proprietary Strategic GPCRs/StaR® Financials Model GPCR Pipeline GPCR Pipeline Investment Continuing to invest and scale the business Allergan upfront milestone in FY2016 drives P&L variance % change % change (JPY m)1 FY2015 FY2016 (FY15 vs FY16) H1 FY 2016 H1 FY 2017 (H116 vs H11
Slide 19: Thank you!
Listed 2004 in Tokyo (TSE Mothers: 4565) Global management team Thank you! Main scientific campus in the U.K. Market capitalization: c.$2.0bn ➢ World-leader in GPCR-focused drug design based on unique IP protected StaR®1 GPCR technology & enabled SBDD2 platform ➢ Partnered clinical-stage pipeline in
Slide 20: Locations
Locations SOSEI GROUP HEPTARES THERAPEUTICS PMO Hanzomon 11F BioPark, Broadwater Road 2-1 Kojimachi, Chiyoda-ku Welwyn Garden City Tokyo 102-0083 Japan Hertfordshire AL7 3AX United Kingdom 2nd Floor, London BioScience Innovation Centre Grabenstrasse 11a, 2 Royal College Street CH-8952 Schlieren Züri
Sosei Group — 36th Annual J.P. Morgan Healthcare Conference (January 2018) on 6ix